Loading...
•
Mar 31, 2024
Mirum Pharmaceuticals Q1 2024 Earnings Report
Mirum Pharmaceuticals' Q1 2024 financial results were reported with revenue of $69.2 million, reflecting a 137% increase compared to Q1 2023, driven by global product sales.
Key Takeaways
Mirum Pharmaceuticals reported a strong first quarter of 2024, marked by a 137% increase in total revenue to $69.2 million. The company is on track to achieve its full-year revenue guidance of $310 to $320 million. Key achievements include FDA approval of LIVMARLI for cholestatic pruritus in PFIC patients and progress in regulatory and pipeline milestones.
Total revenue for Q1 2024 was $69.2 million, up 137% compared to Q1 2023.
LIVMARLI net sales were $42.8 million, representing a 47% increase year-over-year.
FDA approval was obtained for LIVMARLI for cholestatic pruritus in PFIC patients.
Cash and cash equivalents totaled $302.8 million as of March 31, 2024.
Forward Guidance
Mirum Pharmaceuticals anticipates continued demand growth and reiterates full year guidance of $310-$320 million.
Positive Outlook
- Continued demand growth
- Full year guidance of $310-$320 million
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...